GSK Ponied Up $2.4B In Legal Charges In 2nd Quarter
GlaxoSmithKline PLC has disclosed a whopping £1.57 billion ($2.36 billion) legal charge tied to product liability and antitrust settlements over its troubled drugs Paxil and Avandia, revealing for the first time...To view the full article, register now.
Already a subscriber? Click here to view full article